Several life sciences companies and life science-focused real estate firms announced expansion plans as 2021 comes to an end.
JLL’s life sciences experts anticipate that Big Pharma during 2019 will adopt agile real estate strategies and more entrepreneurial approaches to reinvent R&D and compete with smaller enterprises that are doubling down on product innovation and delivery.